Instil Bio

Instil Bio Deferred Tax Liabilities

Deferred Tax Liabilities of Instil Bio (TIL) as of Oct 31, 2026.

Deferred Tax Liabilities

0.00USD

Last updated:

Deferred Tax Liabilities of Instil Bio is 2022 0.00 USD. Deferred Tax Liabilities of Instil Bio was 2021 2.40 M USD. It decreases by % lower compared to the previous year.

The Instil Bio Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2019
0.00 USD
Jan 1, 2020
2.50 M USD
Jan 1, 2021
2.40 M USD
Jan 1, 2022
0.00 USD
The Instil Bio Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
0.00USD-100.00%
2.40 MUSD-4.00%
2.50 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Instil Bio Stock analysis

What does Instil Bio do? Instil Bio Inc develops autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, focusing on advanced melanoma and solid tumors. The company's lead product ITIL-168 targets PD-1-inhibitor relapsed or refractory advanced melanoma, while ITIL-306 uses its Co-Stimulatory Antigen Receptor (CoStAR) platform to recognize folate receptor alpha (FOLR1) on tumors like ovarian, uterine, NSCLC, and renal cancer. The company advances these therapies through clinical development as a clinical-stage biopharmaceutical firm. Its pipeline includes autologous TIL therapies and genetically engineered CoStAR-TIL therapies for multiple cancer types. Instil Bio Inc generates revenue through the development and potential future commercialization of its TIL therapy pipeline. The company's primary focus is on advancing ITIL-168 for advanced melanoma and ITIL-306 for FOLR1-expressing tumors, targeting patients with relapsed or refractory cancers. The firm's clinical-stage status indicates it is currently in development phase without commercial products, so revenue likely comes from partnerships, grants, or future product sales once approved. The company's key segments are cancer patients requiring novel cell therapies, particularly those with melanoma and FOLR1-positive solid tumors. Instil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instil Bio stock

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Instil Bio since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Instil Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Instil Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Instil Bio